Biolux Technology, a leader in advanced light-accelerated orthodontics, has secured CHF 4 million in seed fund stage from European venture capital firm redalpine and Revere Partners, the only venture capital fund focused on oral health. The capital will be used to launch a smart digital platform for its flagship product, OrthoPulse, offering real-time monitoring and treatment optimization for both orthodontists and patients.
In 2023, orthodontic market valued at USD 9 billion (12 million cases) and expected to grow at 15% CAGR to reach USD 21 billion by 2030 (30 million cases). Biolux Technology, based in Geneva with a team located worldwide, is a leading innovator in this market, offering advanced technologies that improve patient outcomes and treatment experiences.
The company’s flagship product, OrthoPulse uses safe near-infrared light therapy to accelerates tooth movement, cutting treatment times by up to 50%. The product features patented light-accelerated technology and an exceptionally low failure rate for more reliable treatment. The approach shortens the orthodontic process and tackles a critical issue in patient care - longer treatments often lead to reduced compliance and more expensive, time-consuming refinements.
The company has now raised fresh capital from leading European VC redalpine and Revere Partners to accelerate the development of OrthoPulse, advance clinical research, and develop innovative solutions that improve patient outcomes and revolutionize orthodontic treatment worldwide. This will further OrthoPulse’s mission to enhance orthodontic treatments through cutting-edge technology and research-driven innovations.
Alongside these developments, Biolux Technology also announced the appointment of Raphael Pascaud as Chairman of the Board. Pascaud brings a wealth of leadership experience from his roles on various boards and executive positions in the dental industry, including at companies like DentalMonitoring and Align Technology. With his deep industry expertise, he will help in steering Biolux through its next phase of growth and innovation.
Marcel Pordes, CEO of Biolux Technology, said: “We are thrilled to partner with both redalpine and Revere Partners, and welcome Raphael Pascaud as our Chairman. This investment, along with our new digital platform for OrthoPulse, represents a critical milestone in our journey to revolutionize orthodontics. We are committed to providing patients with faster, more efficient treatment options, and ensuring orthodontists have the tools they need to deliver exceptional care.”
Daniel Dillinger, Principal at redalpine, said: “Biolux is already transforming orthodontics and delivering exceptional patient outcomes with its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse. We’re delighted to partner with the Biolux team as they enter the next phase of growth, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the U.S. market.”
(Press release/RAN)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines